Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | APAF1 | O14727 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3271284 | 0.90 | SIGMAR1 (0.48) | LMNAALDH1A1MAPK1POLBALOX15 | |
| SCHEMBL13164692 | 0.83 | ALDH1A1 (0.49) | LMNAALDH1A1MAPK1SIGMAR1LTA4H | |
| SCHEMBL13520306 | 0.82 | SIGMAR1 (0.48) | L3MBTL1ALDH1A1ALOX15CASP1HSD17B10 | |
| SCHEMBL16870109 | 0.82 | SIGMAR1 (0.45) | KMT2ASIGMAR1LTA4HPARP1 | |
| SCHEMBL10118898 | 0.82 | LMNA (0.41) | LMNAL3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL23008642 | 0.81 | SLC2A1 (0.38) | SIGMAR1LTA4HPARP1SLC2A1 | |
| SCHEMBL8851013 | 0.81 | SMN1; SMN2 (0.58) | L3MBTL1ALDH1A1MEN1KMT2AMAPK1 | |
| SCHEMBL3440308 | 0.81 | LOXL2 (0.50) | LMNAALDH1A1MAPK1POLBMAPT | |
| SCHEMBL14438280 | 0.79 | IDO1 (0.52) | L3MBTL1ALDH1A1MEN1KMT2AMAPK1 | |
| SCHEMBL6613714 | 0.79 | ITGB1 (0.53) | ALDH1A1SIGMAR1LTA4HPARP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-11679109-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | KEZAR LIFE SCIENCES (US) | 2023-02-14 | — | — | US | disclosed |
| US-11560422-B2 | Sulfonamide-containing linkage systems for drug conjugates | ZYMEWORKS INC. | 2023-01-24 | — | — | US | disclosed |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-12-22 | — | — | US | disclosed |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-07-29 | — | — | US | disclosed |
| US-20210078974-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2021-03-18 | — | — | US | disclosed |
| US-20210060188-A1 | TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2021-03-04 | — | — | US | disclosed |
| US-20170087258-A1 | TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2017-03-30 | — | — | US | disclosed |
| US-20170029490-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | ZYMEWORKS INC. (CA) | 2017-02-02 | — | — | US | disclosed |
| EP-1857459-A2 | Pyrazolopyrimidine compound and a process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 2007-11-21 | — | — | EP | disclosed |
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | LMNA 4560/4885L3MBTL1 4553/4885ALDH1A1 2904/4885 |
| US-20210060188-A1 | TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | FCGR2A, PAICS, CD47 | LMNA 2921/4885L3MBTL1 796/4885ALDH1A1 2533/4885 |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | LMNA 1656/4885L3MBTL1 1394/4885ALDH1A1 2776/4885 |
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | SEC61B, SEC61A1, SEC61G | LMNA 4550/4885L3MBTL1 4760/4885ALDH1A1 4848/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | LMNA 341/4885L3MBTL1 2934/4885ALDH1A1 2230/4885 |
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | LMNA 980/4885L3MBTL1 1827/4885ALDH1A1 3473/4885 |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | LMNA 1656/4885L3MBTL1 1394/4885ALDH1A1 2776/4885 |
| US-20170087258-A1 | TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | FCGR2A, PAICS, CD47 | LMNA 2921/4885L3MBTL1 796/4885ALDH1A1 2533/4885 |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | LMNA 1656/4885L3MBTL1 1394/4885ALDH1A1 2776/4885 |
| US-11679109-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCA2, SMARCC2 | LMNA 341/4885L3MBTL1 2934/4885ALDH1A1 2230/4885 |
| US-11560422-B2 | Sulfonamide-containing linkage systems for drug conjugates | MPST, TPST2, SULT1A1 | LMNA 1797/4885L3MBTL1 1016/4885ALDH1A1 1011/4885 |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | LMNA 1656/4885L3MBTL1 1394/4885ALDH1A1 2776/4885 |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | LMNA 1186/4885L3MBTL1 2534/4885ALDH1A1 3701/4885 |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | LMNA 4448/4885L3MBTL1 4748/4885ALDH1A1 4834/4885 |
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | GABRB1, GABRB3, GABRB2 | LMNA 3033/4885L3MBTL1 967/4885ALDH1A1 1833/4885 |
| US-20210078974-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | LMNA 4555/4885L3MBTL1 4721/4885ALDH1A1 4817/4885 |
| US-20170029490-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | MPST, TPST2, SULT1A1 | LMNA 1797/4885L3MBTL1 1016/4885ALDH1A1 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.